ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0690

Impact of Achieving 2016 ACR/EULAR Response Criteria on Patient Centered Outcome Measures in Myositis

Didem Saygin1, Siamak Moghadam-Kia2, Chester Oddis2, Dana Ascherman2, Nicole Neiman2, Diane Koontz2 and Rohit Aggarwal2, 1University of Chicago, Chicago, IL, 2University of Pittsburgh, Pittsburgh, PA

Meeting: ACR Convergence 2021

Keywords: Myositis, Outcome measures, Patient reported outcomes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Muscle Biology, Myositis & Myopathies Poster (0683–0722)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: The 2016 ACR/EULAR Myositis Response Criteria represent a composite measure that is increasingly being used as a primary end point in myositis clinical trials. The total improvement score (TIS) is calculated using differentially-weighted changes in six myositis core set measures, with thresholds for minimal, moderate and major improvement. It is unclear if achievement of these improvement levels truly reflects changes in symptoms, physical function, and physical activity in myositis patients. In this study, we examined the impact of achieving ACR-EULAR response criteria on patient-centered outcome measures.

Methods: Myositis patients were consecutively enrolled in an observational study with baseline, 3- and 6-month visits where six core set measures [extra-muscular, patient global, and physician global disease activity, manual muscle testing, HAQ-DI, and creatine kinase levels] were evaluated and TIS was calculated for each visit (https://www.niehs.nih.gov/research/resources/imacs/response_criteria/adult.html). The patient centered outcome measures included fatigue (VAS, SF-36), pain (VAS, SF-36), muscle strength (dynamometry), patient reported physical function (PROMIS PF-20, SF-36), task oriented physical function tests [sit-to-stand, timed up-and-go, and six-min walk test] and physical activity (Actigraph). Wilcoxon signed-rank test was used to assess significance of change in outcome measures over 3- and 6-months. Relative changes in outcome measures were compared between patients with improvement vs. those without improvement by using Mann-Whitney U test. Spearman correlation was used for correlations between TIS and changes in specified outcome measures.

Results: Fifty myositis patients were enrolled [mean age: 52, 60% female, 94% white], including 6 PM, 24 DM, 9 necrotizing myopathy and 11 with anti-synthetase syndrome. As per ACR/EULAR criteria, 22 patients had TIS scores satisfying criteria for improvement (13 minimal, 7 moderate, 2 major) at 3-months. Patient centered outcome measures including fatigue, pain, muscle strength, patient reported, and task oriented physical function measures demonstrated significantly greater changes in patients who met ACR/EULAR response criteria of at least minimal improvement compared to those who did not (Table 1). TIS correlated moderately-strongly with relative changes in most patient-centered outcome measures (Table 2). Similar results were noted at 6-months (n=39). Percentage agreement of improvement per TIS was 62% with patient-reported improvement and 90% with physician-reported improvement at 6-months. Patients who had at least minimal improvement also demonstrated significant improvement in pain, fatigue, muscle strength, PROMIS-PF, and task-oriented physical function tests over 6-months.

Conclusion: Achieving improvement using the ACR/EULAR myositis response criteria was accompanied by significant improvement in several patient centered outcome measures including fatigue, pain, muscle strength, physical function, and physical activity. Our results reinforce the validity of the ACR/EULAR myositis response criteria and support their use as a clinically meaningful metric of improvement.

Table 1. Relative percent changes in patient-reported and clinical outcome measures [median (IQR)] using 2016 ACR EULAR myositis response criteria at 3 and 6 months

Table 2. Correlations of outcome measures with total improvement score using 2016 ACR/EULAR myositis response criteria at 3 and 6 months.


Disclosures: D. Saygin, None; S. Moghadam-Kia, None; C. Oddis, Genentech, 5, Pfizer, 2, Corbus, 5, CSL Behring, 5, EMD Serono, 2, 5; D. Ascherman, None; N. Neiman, None; D. Koontz, None; R. Aggarwal, Mallinckrodt, 1, 5, Bristol Myers-Squibb, 2, 5, Pfizer, 2, Genentech, 5, Orphazyme, 1, 2, CSL Behring, 1, 2, AstraZeneca, 2, Kezar, 2, Q32, 2, 5, Alexion, 2, Argenx, 2, Boehringer Ingelheim, 2, Corbus, 2, EMD Serono, 2, 5, Janssen, 2, Kyverna, 2, Octapharma, 1, 2.

To cite this abstract in AMA style:

Saygin D, Moghadam-Kia S, Oddis C, Ascherman D, Neiman N, Koontz D, Aggarwal R. Impact of Achieving 2016 ACR/EULAR Response Criteria on Patient Centered Outcome Measures in Myositis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/impact-of-achieving-2016-acr-eular-response-criteria-on-patient-centered-outcome-measures-in-myositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-achieving-2016-acr-eular-response-criteria-on-patient-centered-outcome-measures-in-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology